When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant?
Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a po...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Barnabé, Cheryl [verfasserIn] Hurst, Lorne [verfasserIn] Alowami, Salem [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2003 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology - Springer-Verlag, 2001, 7(2003), 5 vom: Okt., Seite 387-389 |
|---|---|
| Übergeordnetes Werk: |
volume:7 ; year:2003 ; number:5 ; month:10 ; pages:387-389 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10227-002-0157-7 |
|---|
| Katalog-ID: |
SPR009159037 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR009159037 | ||
| 003 | DE-627 | ||
| 005 | 20230519184200.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2003 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10227-002-0157-7 |2 doi | |
| 035 | |a (DE-627)SPR009159037 | ||
| 035 | |a (SPR)s10227-002-0157-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barnabé, Cheryl |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? |
| 264 | 1 | |c 2003 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis. | ||
| 650 | 4 | |a Tacrolimus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mycophenolate Mofetil |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pyoderma Gangrenosum |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Clofazimine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Topical Tacrolimus |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Hurst, Lorne |e verfasserin |4 aut | |
| 700 | 1 | |a Alowami, Salem |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology |d Springer-Verlag, 2001 |g 7(2003), 5 vom: Okt., Seite 387-389 |w (DE-627)SPR009157867 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2003 |g number:5 |g month:10 |g pages:387-389 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10227-002-0157-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2003 |e 5 |c 10 |h 387-389 | ||
| author_variant |
c b cb l h lh s a sa |
|---|---|
| matchkey_str |
barnabcherylhurstlornealowamisalem:2003----:hnseactatydraageout |
| hierarchy_sort_str |
2003 |
| publishDate |
2003 |
| allfields |
10.1007/s10227-002-0157-7 doi (DE-627)SPR009159037 (SPR)s10227-002-0157-7-e DE-627 ger DE-627 rakwb eng Barnabé, Cheryl verfasserin aut When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis. Tacrolimus (dpeaa)DE-He213 Mycophenolate Mofetil (dpeaa)DE-He213 Pyoderma Gangrenosum (dpeaa)DE-He213 Clofazimine (dpeaa)DE-He213 Topical Tacrolimus (dpeaa)DE-He213 Hurst, Lorne verfasserin aut Alowami, Salem verfasserin aut Enthalten in Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology Springer-Verlag, 2001 7(2003), 5 vom: Okt., Seite 387-389 (DE-627)SPR009157867 nnns volume:7 year:2003 number:5 month:10 pages:387-389 https://dx.doi.org/10.1007/s10227-002-0157-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 7 2003 5 10 387-389 |
| spelling |
10.1007/s10227-002-0157-7 doi (DE-627)SPR009159037 (SPR)s10227-002-0157-7-e DE-627 ger DE-627 rakwb eng Barnabé, Cheryl verfasserin aut When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis. Tacrolimus (dpeaa)DE-He213 Mycophenolate Mofetil (dpeaa)DE-He213 Pyoderma Gangrenosum (dpeaa)DE-He213 Clofazimine (dpeaa)DE-He213 Topical Tacrolimus (dpeaa)DE-He213 Hurst, Lorne verfasserin aut Alowami, Salem verfasserin aut Enthalten in Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology Springer-Verlag, 2001 7(2003), 5 vom: Okt., Seite 387-389 (DE-627)SPR009157867 nnns volume:7 year:2003 number:5 month:10 pages:387-389 https://dx.doi.org/10.1007/s10227-002-0157-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 7 2003 5 10 387-389 |
| allfields_unstemmed |
10.1007/s10227-002-0157-7 doi (DE-627)SPR009159037 (SPR)s10227-002-0157-7-e DE-627 ger DE-627 rakwb eng Barnabé, Cheryl verfasserin aut When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis. Tacrolimus (dpeaa)DE-He213 Mycophenolate Mofetil (dpeaa)DE-He213 Pyoderma Gangrenosum (dpeaa)DE-He213 Clofazimine (dpeaa)DE-He213 Topical Tacrolimus (dpeaa)DE-He213 Hurst, Lorne verfasserin aut Alowami, Salem verfasserin aut Enthalten in Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology Springer-Verlag, 2001 7(2003), 5 vom: Okt., Seite 387-389 (DE-627)SPR009157867 nnns volume:7 year:2003 number:5 month:10 pages:387-389 https://dx.doi.org/10.1007/s10227-002-0157-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 7 2003 5 10 387-389 |
| allfieldsGer |
10.1007/s10227-002-0157-7 doi (DE-627)SPR009159037 (SPR)s10227-002-0157-7-e DE-627 ger DE-627 rakwb eng Barnabé, Cheryl verfasserin aut When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis. Tacrolimus (dpeaa)DE-He213 Mycophenolate Mofetil (dpeaa)DE-He213 Pyoderma Gangrenosum (dpeaa)DE-He213 Clofazimine (dpeaa)DE-He213 Topical Tacrolimus (dpeaa)DE-He213 Hurst, Lorne verfasserin aut Alowami, Salem verfasserin aut Enthalten in Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology Springer-Verlag, 2001 7(2003), 5 vom: Okt., Seite 387-389 (DE-627)SPR009157867 nnns volume:7 year:2003 number:5 month:10 pages:387-389 https://dx.doi.org/10.1007/s10227-002-0157-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 7 2003 5 10 387-389 |
| allfieldsSound |
10.1007/s10227-002-0157-7 doi (DE-627)SPR009159037 (SPR)s10227-002-0157-7-e DE-627 ger DE-627 rakwb eng Barnabé, Cheryl verfasserin aut When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? 2003 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis. Tacrolimus (dpeaa)DE-He213 Mycophenolate Mofetil (dpeaa)DE-He213 Pyoderma Gangrenosum (dpeaa)DE-He213 Clofazimine (dpeaa)DE-He213 Topical Tacrolimus (dpeaa)DE-He213 Hurst, Lorne verfasserin aut Alowami, Salem verfasserin aut Enthalten in Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology Springer-Verlag, 2001 7(2003), 5 vom: Okt., Seite 387-389 (DE-627)SPR009157867 nnns volume:7 year:2003 number:5 month:10 pages:387-389 https://dx.doi.org/10.1007/s10227-002-0157-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 7 2003 5 10 387-389 |
| language |
English |
| source |
Enthalten in Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology 7(2003), 5 vom: Okt., Seite 387-389 volume:7 year:2003 number:5 month:10 pages:387-389 |
| sourceStr |
Enthalten in Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology 7(2003), 5 vom: Okt., Seite 387-389 volume:7 year:2003 number:5 month:10 pages:387-389 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Tacrolimus Mycophenolate Mofetil Pyoderma Gangrenosum Clofazimine Topical Tacrolimus |
| isfreeaccess_bool |
false |
| container_title |
Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology |
| authorswithroles_txt_mv |
Barnabé, Cheryl @@aut@@ Hurst, Lorne @@aut@@ Alowami, Salem @@aut@@ |
| publishDateDaySort_date |
2003-10-01T00:00:00Z |
| hierarchy_top_id |
SPR009157867 |
| id |
SPR009159037 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009159037</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519184200.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2003 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10227-002-0157-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009159037</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10227-002-0157-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Barnabé, Cheryl</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2003</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tacrolimus</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mycophenolate Mofetil</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pyoderma Gangrenosum</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clofazimine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Topical Tacrolimus</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hurst, Lorne</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alowami, Salem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology</subfield><subfield code="d">Springer-Verlag, 2001</subfield><subfield code="g">7(2003), 5 vom: Okt., Seite 387-389</subfield><subfield code="w">(DE-627)SPR009157867</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2003</subfield><subfield code="g">number:5</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:387-389</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10227-002-0157-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2003</subfield><subfield code="e">5</subfield><subfield code="c">10</subfield><subfield code="h">387-389</subfield></datafield></record></collection>
|
| author |
Barnabé, Cheryl |
| spellingShingle |
Barnabé, Cheryl misc Tacrolimus misc Mycophenolate Mofetil misc Pyoderma Gangrenosum misc Clofazimine misc Topical Tacrolimus When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? |
| authorStr |
Barnabé, Cheryl |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR009157867 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? Tacrolimus (dpeaa)DE-He213 Mycophenolate Mofetil (dpeaa)DE-He213 Pyoderma Gangrenosum (dpeaa)DE-He213 Clofazimine (dpeaa)DE-He213 Topical Tacrolimus (dpeaa)DE-He213 |
| topic |
misc Tacrolimus misc Mycophenolate Mofetil misc Pyoderma Gangrenosum misc Clofazimine misc Topical Tacrolimus |
| topic_unstemmed |
misc Tacrolimus misc Mycophenolate Mofetil misc Pyoderma Gangrenosum misc Clofazimine misc Topical Tacrolimus |
| topic_browse |
misc Tacrolimus misc Mycophenolate Mofetil misc Pyoderma Gangrenosum misc Clofazimine misc Topical Tacrolimus |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology |
| hierarchy_parent_id |
SPR009157867 |
| hierarchy_top_title |
Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR009157867 |
| title |
When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? |
| ctrlnum |
(DE-627)SPR009159037 (SPR)s10227-002-0157-7-e |
| title_full |
When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? |
| author_sort |
Barnabé, Cheryl |
| journal |
Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology |
| journalStr |
Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2003 |
| contenttype_str_mv |
txt |
| container_start_page |
387 |
| author_browse |
Barnabé, Cheryl Hurst, Lorne Alowami, Salem |
| container_volume |
7 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Barnabé, Cheryl |
| doi_str_mv |
10.1007/s10227-002-0157-7 |
| author2-role |
verfasserin |
| title_sort |
when is recalcitrant pyoderma gangrenosum truly recalcitrant? |
| title_auth |
When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? |
| abstract |
Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis. |
| abstractGer |
Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis. |
| abstract_unstemmed |
Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
5 |
| title_short |
When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant? |
| url |
https://dx.doi.org/10.1007/s10227-002-0157-7 |
| remote_bool |
true |
| author2 |
Hurst, Lorne Alowami, Salem |
| author2Str |
Hurst, Lorne Alowami, Salem |
| ppnlink |
SPR009157867 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10227-002-0157-7 |
| up_date |
2024-07-04T00:54:13.834Z |
| _version_ |
1803607819005460481 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009159037</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519184200.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2003 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10227-002-0157-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009159037</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10227-002-0157-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Barnabé, Cheryl</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">When Is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2003</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Background: The literature supports many different therapies used in recalcitrant pyoderma gangrenosum, which suggests that the pathophysiology is not yet understood. Our hypothesis is that certain patient demographic factors, including age or size of ulcer at presentation, may predict a poor clinical outcome. Objective: The goal of our study was to stimulate an analysis of pyoderma gangrenosum treatment failures to identify predisposing conditions that would increase the likelihood of failure. Conclusion: Patients older than 50 years of age or with an ulcer greater than 25 cm in diameter may have a poor outcome, but a systematic review of pyoderma gangrenosum treatment failures should be undertaken to support this hypothesis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Tacrolimus</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mycophenolate Mofetil</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pyoderma Gangrenosum</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clofazimine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Topical Tacrolimus</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hurst, Lorne</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alowami, Salem</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology</subfield><subfield code="d">Springer-Verlag, 2001</subfield><subfield code="g">7(2003), 5 vom: Okt., Seite 387-389</subfield><subfield code="w">(DE-627)SPR009157867</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2003</subfield><subfield code="g">number:5</subfield><subfield code="g">month:10</subfield><subfield code="g">pages:387-389</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10227-002-0157-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2003</subfield><subfield code="e">5</subfield><subfield code="c">10</subfield><subfield code="h">387-389</subfield></datafield></record></collection>
|
| score |
7.4013023 |